Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis, Relapsing-remitting”

720 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 720 results

Large-scale testing (Phase 3)Study completedNCT01707992
What this trial is testing

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 2,199
Testing effectiveness (Phase 2)Study completedNCT00228163
What this trial is testing

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Who this might be right for
Multiple Sclerosis
Sanofi 147
Large-scale testing (Phase 3)Study completedNCT00027300
What this trial is testing

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 900
Large-scale testing (Phase 3)Study completedNCT03774407
What this trial is testing

Vaginal Estriol in Multiple Sclerosis

Who this might be right for
Multiple SclerosisNeurogenic Bladder
Texas Tech University Health Sciences Center 21
Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Post-approval studies (Phase 4)Study completedNCT02048072
What this trial is testing

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

Who this might be right for
Multiple SclerosisAutonomic Nervous System Dysfunction
Jochen Vehoff 33
Testing effectiveness (Phase 2)Ended earlyNCT04767698
What this trial is testing

Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Johns Hopkins University 4
Not applicableStudy completedNCT00787657
What this trial is testing

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Bayer 1,723
Large-scale testing (Phase 3)Study completedNCT00134563
What this trial is testing

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sanofi 1,088
Testing effectiveness (Phase 2)Study completedNCT00882999
What this trial is testing

Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Eli Lilly and Company 245
Not applicableStudy completedNCT05366036
What this trial is testing

Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
Eisai Korea Inc. 172
Testing effectiveness (Phase 2)Study completedNCT02782858
What this trial is testing

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GeNeuro SA 270
Not applicableStudy completedNCT04997148
What this trial is testing

Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 116
Not applicableStudy completedNCT01456416
What this trial is testing

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Southern California 10
Testing effectiveness (Phase 2)Study completedNCT00879658
What this trial is testing

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 297
Testing effectiveness (Phase 2)Study completedNCT00676715
What this trial is testing

The Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 220
Early research (Phase 1)UnknownNCT02903537
What this trial is testing

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Fundació Institut Germans Trias i Pujol 16
Large-scale testing (Phase 3)Study completedNCT02727907
What this trial is testing

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biocad 163
Testing effectiveness (Phase 2)Study completedNCT00168701
What this trial is testing

Efficacy and Safety of BG00012 in MS

Who this might be right for
Multiple Sclerosis
Biogen 260
Not applicableEnded earlyNCT00398528
What this trial is testing

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Neurognostics 48
Load More Results